HighVista Strategies’s Cogent Biosciences COGT Stock Holding History

HighVista Strategies’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.58M	Sell	197,051 -139,616	-41%	-$5.16M	2.09%	4
2025 Q4	$12M	Sell	336,667 -125,738	-27%	-$3.53M	3.08%	3
2025 Q3	$6.64M	Buy	462,405 +179,219	+63%	+$2.12M	1.63%	14
2025 Q2	$2.03M	Buy	283,186 +3,513	+1%	+$19.5K	0.75%	42
2025 Q1	$1.68M	Hold	279,673	–	–	0.65%	53
2024 Q4	$2.18M	Buy	279,673 +54,040	+24%	+$539K	0.81%	40
2024 Q3	$2.44M	Sell	225,633 -55,460	-20%	-$540K	0.84%	35
2024 Q2	$2.37M	Hold	281,093	–	–	0.87%	34
2024 Q1	$1.89M	Hold	281,093	–	–	0.67%	51
2023 Q4	$1.65M	Buy	281,093 +82,506	+42%	+$632K	0.6%	58
2023 Q3	$1.94M	Sell	198,587 -17,543	-8%	-$208K	0.9%	36
2023 Q2	$2.56M	Buy	216,130 +32,146	+17%	+$369K	1.17%	27
2023 Q1	$1.99M	Hold	183,984	–	–	1.62%	22
2022 Q4	$2.13M	Buy	183,984 +65,049	+55%	+$806K	1.26%	23
2022 Q3	$1.77M	Buy	+118,935	New	+$1.63M	1.01%	32

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

HighVista Strategies's COGT Position: Q1 2026 in Review

HighVista Strategies reduced its Cogent Biosciences (COGT) stake by 41% in Q1 2026, selling an estimated $5.16M and leaving 197,051 shares worth $7.58M. The position accounts for 2.09% of the portfolio, ranked #4.

HighVista Strategies first reported a position in COGT in Q3 2022 and has held it in 15 quarters since. The position peaked at $12M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

HighVista Strategies held 197,051 shares of Cogent Biosciences worth $7.58M as of Q1 2026.
HighVista Strategies sold 139,616 Cogent Biosciences shares in Q1 2026, an estimated $5.16M.
Cogent Biosciences made up 2.09% of HighVista Strategies's portfolio in Q1 2026, its #4 holding.
HighVista Strategies first reported a position in Cogent Biosciences in Q3 2022 and has held it in 15 quarters since.
HighVista Strategies's Cogent Biosciences position peaked at $12M in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.